The Assessment Group, April 2011, Pages: 26
US Oncologist Survey: Optimizing Treatment for Stage IV Follicular B-Cell Non-Hodgkin’s Lymphoma
A patient specific case scenario on advanced non-Hodgkin’s lymphoma involving a patient with stage
The Assessment Group, April 2011, Pages: 28
prescribing data that you are missing - directly from high-prescribing US oncologists on advanced non-Hodgkin’s lymphoma.
Treatment decisions for advanced stages of cancer are difficult to track
The Assessment Group, April 2011, Pages: 61
Experience real patient situations that progressively unfold, presented to a representative sample of 158 US oncologists who manage 11 or more patients monthly with non-Hodgkin’s lymphoma
Global Industry Analysts, Inc., April 2010, Pages: 752
of Study I-3
Types of Lymphomas I-3
Hodgkin’s lymphoma I-3
Non-Hodgkin’s lymphoma I-3
II. Executive Summary
1. GLOBAL OUTLOOK II-1
Global Lymphoma Therapeutics Market to Surge II-1
Europe Leads the Global
GBI Research, Jan 2011, Pages: 122
.
- Market data on the therapeutic landscape which covers lung cancer, breast cancer, colorectal cancer, non-hodgkin’s lymphoma and prostate cancer, including market size, market share, annual cost of therapy
The Assessment Group, April 2011, Pages: 35
non-Hodgkin’s lymphoma.
Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact
Decision Resources, Inc., Dec 2006, Pages: 24
Non-Hodgkin’s lymphoma, consisting of 29 different malignancies of the lymphatic system, is a devastating disease: although treatable, only a small percentage of these cancers are curable
GlobalData, May 2011, Pages: 5
Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-HodgkinLymphoma)
Summary
The group of cancers that originate
GBI Research, Dec 2010, Pages: 126
of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL).
Scope
The report covers:
- Data and analysis
GBI Research, Dec 2009, Pages: 186
to 2008, forecast forward to 2015
- Analysis of the leading therapeutic segments including lung cancer, breast cancer, prostate cancer, colorectal cancer and Non-Hodgkin’s Lymphoma.
- Analysis
Frost & Sullivan, April 2008, Pages: 65
and Neck Cancer
- Liver Cancer
- Lung Cancer
- Melanoma
- Non-HodgkinLymphoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cell Carcinoma
Addiction Vaccine Pipeline by Disease
John Wiley and Sons Ltd, Jan 2010, Pages: 576
cancer.
21 Cancer from an unknown primary site.
22 Skin cancer.
23 Bone and soft-tissue sarcomas.
24 Paediatric malignancies.
25 Hodgkin's disease.
26 Non-Hodgkin's lymphomas.
27 Myeloma and other
GBI Research, Dec 2011, Pages: 215
indications, which includes breast cancer, colorectal cancer, Non-Hodgkin’s lymphoma (NHL), Non-Small Cell Lung Cancer (NSCLC), prostate cancer, ovarian cancer, cervical cancer and head and neck cancer
GlobalData, Dec 2010, Pages: 106
Non-HodgkinLymphoma Global Clinical Trials Review, Q4, 2010
Summary
Our clinical trial report, “Non-HodgkinLymphoma Global Clinical Trials Review, Q4, 2010"” provides data on the Non-Hodgkin
Jain PharmaBiotech, Feb 2012, Pages: 639
of neuroblastoma
Non-Hodgkin's lymphoma
Pixantrone
Non-small cell lung cancer
Aerosol delivery of anticancer agents for lung cancer
Aerosol gene delivery for lung cancer
Complex nanoscale pulmonary delivery
Spectra Intelligence, April 2006, Pages: 369
Breast Cancer
Prostate Cancer
Ovarian Cancer
Testicular CancerCancers of Haematopoetic Origin - The Leukaemias
Leukaemias
Hodgkin’s Disease
Non-Hodgkin’s Lymphoma
Chemotherapy Drugs Approved
